Abeona Therapeutics (NASDAQ:ABEO) target price raised to $14.00, issued a report today by Maxim Group
- Updated: September 28, 2016
Abeona Therapeutics (NASDAQ:ABEO) had its stock price target increased to $14.00 by Maxim Group in a report issued Thursday September 29, 2016. The updated target price indicates a possible upside of 1.44% from the company's previous stock price.
Having a price of $5.74, Abeona Therapeutics (NASDAQ:ABEO) traded 2.32% higher on the day. With the last stock price up 77.52% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ABEO has recorded a 50-day average of $4.73 and a two hundred day average of $3.23. Trade Volume was up over the average, with 348,055 shares of ABEO changing hands over the typical 166,791
Recent Performance Chart
Abeona Therapeutics has with a one year low of $2.05 and a one year high of $6.80 and has a market capitalization of $0.
A total of 4 brokerages have issued a ratings update on Abeona Therapeutics. One brokerage rating the company a strong buy, three brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $12.38.
General Company Details For Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.